Related Experiment Video
Updated: Sep 24, 2025
Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
Published on: November 30, 2018
Beta Amyloid and Malondialdehyde Serum Levels' Analysis in Atrial Fibrillation Patients with Cognitive Impairment
Yuliarni Syafrita1, Darwin Amir1, Restu Susanti1
1Department of Neurology, Faculty of Medicine, Andalas University/DR M Djamil Hospital, Padang, West Sumatra, Indonesia.
Insights
Atrial fibrillation (AF) patients with cognitive impairment show lower amyloid beta 42 (Aβ42) and higher malondialdehyde (MDA) serum levels. These biomarkers may indicate cognitive decline in AF patients.
Area of Science:
- Biochemistry
- Neurology
- Cardiology
Background:
- Atrial fibrillation (AF) is a common cardiac dysrhythmia, increasing stroke risk by fivefold.
- AF is increasingly recognized as a risk factor for cognitive impairment and dementia.
- Understanding the biochemical markers associated with cognitive decline in AF is crucial.
Purpose of the Study:
- To investigate differences in serum amyloid beta (Aβ) isoforms (Aβ40 and Aβ42) and malondialdehyde (MDA) levels.
- To compare these biomarker levels between AF patients with and without cognitive impairment.
Main Methods:
- An observational case-control study involving 63 AF patients (38 with cognitive impairment, 25 without).
- Serum levels of MDA, Aβ40, and Aβ42 were measured using ELISA.
- Statistical analysis included Mann-Whitney and chi-squared tests.
Main Results:
- AF patients with cognitive impairment had significantly lower mean Aβ42 levels compared to those without.
- AF patients with cognitive impairment exhibited significantly higher mean MDA levels.
- A trend towards lower Aβ40 levels was observed in the cognitive impairment group, but it was not statistically significant.
Conclusions:
- Significantly lower Aβ42 and higher MDA serum levels are associated with cognitive impairment in AF patients.
- These findings suggest a potential role for Aβ42 and MDA as biomarkers for cognitive decline in atrial fibrillation.
Background:
Atrial fibrillation (AF) is the most commonly encountered cardiac dysrhythmia, and AF patients are five times more likely to have a risk of stroke. Although the effects of stroke on patients are quite severe, lately it has been recognized that AF is associated with the incidence of cognitive impairment and dementia.
Objective:
This study aims to analyze and determine the differences in two isoforms of amyloid beta (Aββ40 and 42) and malondialdehyde (MDA) serum levels in AF patients who experience and who do not experience cognitive impairment.
Methods:
An observational study with case-control design was carried out on 63 people with atrial fibrillation, consisting of 38 people with cognitive impairment and 25 people without cognitive impairment. Examination of MDA and the Aβ40 and Aβ42 levels was carried out by ELISA. The difference level of each variable in the two groups was tested by the Mann-Whitney and χ2 tests, at P ≤ 0.05 significance level.
Results:
Lower mean levels of Aβ42 and higher mean levels of MDA were found in the group with cognitive impairment rather than in the group without cognitive impairment. Lower mean levels of Aβ40 were found in the group with cognitive impairment rather than in the group without cognitive impairment but this difference was not statistically significant.
Conclusion:
Significantly lower levels of Aβ42 and higher levels of MDA were found in the AF patients with cognitive impairment rather than in the AF patients without cognitive impairment.
More Related Videos
07:30Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
